Review
Pharmacology & Pharmacy
Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, Jose M. Carballido, Peter Hausermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau, Gerard Bruin
Summary: Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases with varied symptoms and treatment responses. Secukinumab, a drug targeting IL-17A, has been used for over 6 years in the treatment of these diseases and has specific pharmacological properties.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Clinical Neurology
Rick Dersch, Sebastian Rauer
Summary: This study aimed to update a previous systematic review on the treatment of Lyme neuroborreliosis (LNB) and provide evidence-based recommendations by evaluating the recent literature. The results showed that both doxycycline and beta-lactam antibiotics have similar efficacy in treating LNB, extended antibiotic treatment does not provide any benefit, and the use of steroids in LNB with facial palsy is not recommended.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Review
Rheumatology
Atul Deodhar, Pedro M. Machado, Michael Morup, Vanessa Taieb, Damon Willems, Michelle Orme, David Pritchett, Lianne S. Gensler
Summary: This study compared the efficacy and safety of bimekizumab with other biologic/targeted synthetic DMARDs in nr-axSpA and AS. The results showed that bimekizumab was comparable with other drugs in terms of ASAS outcomes and achieved higher response rates in patients who were predominantly naïve to b/tsDMARDs. Bimekizumab also demonstrated similar safety to other drugs.
Review
Rheumatology
Augusta Ortolan, Casper Webers, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study updated the evidence of non-biological treatments for axSpA, providing a basis for the 2022 ASAS-EULAR recommendations. The results showed that education, exercise, and NSAIDs were efficacious in axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Desiree van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A. Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M. Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip van den Bosch, Thomas Vaux, Huji Xu
Summary: The BE MOBILE 1 and BE MOBILE 2 trials demonstrated that bimekizumab, a dual IL-17A and IL-17F inhibitor, improved efficacy outcomes in patients with axial spondyloarthritis (axSpA) and was well tolerated. These findings support the use of bimekizumab as a potential treatment option for axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Neurosciences
Xuan Zhou, Juncong Du, Yi Liang, Chengcheng Dai, Lili Zhao, Xi Liu, Changhong Tan, Lijuan Mo, Lifen Chen
Summary: Comparing the effectiveness and safety of different drugs for restless legs syndrome (RLS), this network meta-analysis found that cabergoline and pramipexole are the most effective in relieving symptoms, while iron supplements significantly help RLS patients with iron deficiency. These drugs are effective for primary RLS, but data on secondary RLS are insufficient. Additionally, alpha-2-delta ligands and DAs are recommended for their efficacy and tolerability.
FRONTIERS IN NEUROSCIENCE
(2021)
Review
Rheumatology
Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde
Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Cindy L. J. Weinstein, Paula Sliwinska-Stanczyk, Tomas Hala, Marina Stanislav, Anjela Tzontcheva, Ruji Yao, Yuliya Berd, Sean P. Curtis, George Philip
Summary: The GO-BACK study evaluated the efficacy and safety of golimumab withdrawal in non-radiographic axial spondyloarthritis patients who demonstrated inactive disease. The results showed that continued treatment with golimumab was superior in preventing disease flare compared to treatment withdrawal.
Article
Rheumatology
Juergen Braun, Uta Kiltz, Atul Deodhar, Tetsuya Tomita, Maxime Dougados, Rebecca Bolce, David Sandoval, Chen-Yen Lin, Jessica Walsh
Summary: The study aimed to evaluate the efficacy and safety of ixekizumab in patients with radiographic and non-radiographic axial spondyloarthritis for up to 116 weeks. Results showed sustained long-term improvements in both subtypes of axSpA, with similar efficacy for patients receiving the approved every 4 weeks dose. The safety profile of ixekizumab was consistent with previous reports.
Review
Biochemistry & Molecular Biology
Elisa Landucci, Domenico E. Pellegrini-Giampietro, Fabrizio Facchinetti
Summary: Term neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of long-term disability and further research is needed to develop new treatments. When choosing a research model, it is important to consider different experimental models to test the effectiveness of new drugs. Therapeutic hypothermia is already a routine treatment for neonatal encephalopathy, so the selected model must undergo hypothermia to test the translational effects of new or repurposed drugs. Translational research requires initiating treatment after the induction of insult and evaluating the time window for intervention to translate to clinical practice. Hippocampal organotypic slice cultures are a valuable intermediate between cell lines and in vivo models. In vivo models, particularly rodent models, offer flexibility and cost-effectiveness for dose-response testing of pharmacological agents. Large animal models can be used for focused and accurate translational studies, including pharmacokinetics and safety assessments.
Review
Rheumatology
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Biochemistry & Molecular Biology
Sergio Del Vescovo, Vincenzo Venerito, Claudia Iannone, Giuseppe Lopalco
Summary: Axial spondyloarthritis (axial-SpA) is a multifactorial disease characterized by inflammation in sacroiliac joints and spine, bone reabsorption, and aberrant bone deposition, which may lead to ankylosis. The disease pathogenesis involves a complex interplay between genetic, immunological, mechanical, and bioenvironmental factors. HLA-B27 plays a significant role as the most important genetic factor, but the disease can also develop in its absence. The innate immune system and T cell adaptive response both contribute to the onset of axial-SpA, leading to the production of proinflammatory molecules and activation of intracellular pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu
Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Rheumatology
Torsten Diekhoff, Iris Eshed, Felix Radny, Katharina Ziegeler, Fabian Proft, Juliane Greese, Dominik Deppe, Robert Biesen, Kay Geert Hermann, Denis Poddubnyy
Summary: The study found that compared to CT and MRI, X-ray had lower sensitivity and inferior specificity for axSpA. However, CT showed the best inter-rater reliability, highlighting the importance of structural lesions for the differential diagnosis in axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Zhixiu Li, Mohammad Kazim Khan, Sjef M. van der Linden, Bjorn Winkens, Peter M. Villiger, Heinz Baumberger, Hermine van Zandwijk, Muhammad Asim Khan, Matthew A. Brown
Summary: This study found that patients with ankylosing spondylitis (AS) have a higher mortality rate compared to the general population, and healthy individuals carrying the HLA-B27 gene also have a similar risk. Additionally, female patients have a lower life expectancy. However, in the overall European population, the presence of the HLA-B27 gene does not affect survival or the risk of death from cardiovascular disease.
ANNALS OF THE RHEUMATIC DISEASES
(2023)